Received Apr 20, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| YF | YELLOW FEVER (YF-VAX) | SANOFI PASTEUR | UNK | U8711BB | — |
plunger was at an angle when she went to draw up the sodium chloride diluent and it dribbled all down her hand with no reported adverse event; plunger was at an angle when she went to draw up the sodium chloride diluent and it dribbled all down her hand with no reported adverse event; Initial information received on 02-Mar-2026 regarding an unsolicited valid non-serious case received from a nurse. This case involves an unknown age, unknown gender patient who exposed with yellow fever vaccine (YF-VAX) when she went to draw up the sodium chloride diluent and it dribbled all down her hand with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s), family history, and concomitant medications were not provided. On an unknown date the patient was exposed with an unknown dose of suspect yellow fever vaccine solution for injection, strength, (batch: U8711BB, expiry: 31-Jan-2028) for prophylactic vaccination [Immunisation] when she went to draw up the sodium chloride diluent and it dribbled all down her hand with no reported adverse event (accidental exposure to product and exposure via skin contact) (latency: same day). Reportedly, Caller is seeking a replacement diluent for the Yf-vax due to having an issue with a syringe used during preparation. The caller reported that the syringe was their own syringe and not part of the vaccine; that when they were attempting to pull up the diluent it was found that the plunger was at an angle; that the plunger came out and then the vaccine spilled all over the caller's hand. Action taken with yellow fever vaccine was unknown. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Comments: NONE